The 2000 United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) inhibitor guidelines [0.03%]
2000年英国血友病中心医师组织(INHCO)抑制物指南
C R M Hay; United Kingdom Haemophilia Centre Doctors&#x; Organisation (UKHCDO)
C R M Hay; United Kingdom Haemophilia Centre Doctors&#x; Organisation (UKHCDO)
The UKHCDO inhibitor guidelines address the diagnosis and management of patients with haemophilia A, haemophilia B and acquired haemophilia. Recommendations are based on best current practice as reflected in the published evidence base. Man...
The evidence behind inhibitor treatment with recombinant factor VIIa [0.03%]
关于用重组活化第七因子治疗抑制物患者的证据分析
Christopher A Ludlam
Christopher A Ludlam
Over the past 10 years considerable use has been made of recombinant factor VIIa (rFVIIa) for the treatment of patients with inhibitors to coagulation factors. During this time, its place in the management of acute bleeds and surgery has be...
Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors [0.03%]
关于活化凝血酶复合物浓缩剂治疗伴有抑制物的血友病患者的证据
J T Wilde
J T Wilde
FEIBA and Autoplex T have been used to control bleeding in patients with factor VIII or IX inhibitors for over 25 years. The major components of FEIBA are thought to be activated factor X and prothrombin, whereas the main active components ...
Christine A Lee
Christine A Lee
Factor VIII auto- and alloantibodies neutralise porcine factor VIII to a lesser extent than factor VIII of human origin. The reduced reactivity of the porcine molecule, predominantly due to sequence variation in the A2 and C2 domains, has b...
William G Murphy
William G Murphy
Transfusion of blood and blood products has been associated with transmission of infectious agents. However, it is probable that blood products are currently very safe and that pooled virus-inactivated products from remunerated donors are n...